yingweiwo

Etravirine (R165335; TMC125)

Alias: R-165335;TMC-125;R165335;TMC125;R 165335; TMC 125;R165335; Etravirine. Intelence.
Cat No.:V1828 Purity: ≥98%
Etravirine (formerly TMC-125; R-165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.
Etravirine (R165335; TMC125)
Etravirine (R165335; TMC125) Chemical Structure CAS No.: 269055-15-4
Product category: Reverse Transcriptase
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

Other Forms of Etravirine (R165335; TMC125):

  • Etravirine D4
  • Etravirine-d8
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Etravirine (formerly TMC-125; R-165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. It was also approved in 2008. Etravirine, in combination with other anti-retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other antiretroviral agents.

Biological Activity I Assay Protocols (From Reference)
ln Vitro
TMC125 exhibits significant efficacy against HIV-2 (EC50=3.5 μM) and wild-type HIV-1 (50% effective concentration [EC50]=1.4 to 4.8 nM). A number of HIV-1 group M subtypes, circulating recombinant forms, and a group O virus are also inhibited by TMC125. 19 viruses had TMC125 activity with an EC50 of less than 5 nM[1].
ln Vivo
The development of resistance to etravirine is very genetically resistant. TMC125 has demonstrated activity against HIV resistance to currently available NNRTIs in phase IIb trials involving treatment-experienced individuals, including those infected with virus resistant to NNRTIs and protease inhibitors (PIs), while maintaining a tolerability profile comparable to the control group[2].
Animal Protocol
NA
NA
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Maximum oral absorption is achieved in 2.5-4 hours. Absorption is unaffected by the concomitant use of oral ranitidine or omeprazole, which decrease gastric acidity. Administration under fasting conditions resulted in a near 50% decrease in systemic exposure (AUC) when compared to administration after a meal.
After a 800mg dose of radio-labelled etraverine, 93.7% was found to undergo fecal elimination, with 81.2% - 86.4% eliminated unchanged. 1.2% of the dose was renally eliminated, changed. Etravirine is dialyzable (hemodialysis).
Distribution of etravirine into compartments other than plasma has not been evaluated in humans.
Renal clearance of etravirine is negligible (<1.2%), thus no dose adjustments are required in patients with renal impairment. Clearance is shown to be reduced in patients with Hepatitis B and/or co-infection, however, the safety profile of etravirine does not call for dosage adjustments.
Metabolism / Metabolites
Metabolized (in vitro) by the liver CYP450 enzymes: CYP3A4, CYP2C9, CYP2C19. The major metabolites formed by a methyl hydroxylation of the dimethylbenzonitrile moiety retained less than 90% of etravirine's activity.
Biological Half-Life
Half life of 9.05-41 hours.
Toxicity/Toxicokinetics
Hepatotoxicity
Serum aminotransferase elevations occur in a high proportion of patients on etravirine therapy, but increases above 5 times the upper limit of normal occur in only 2% to 3% of patients; this rate may be higher in patients who have hepatitis C coinfection. In most studies, the rate of liver enzyme elevations was no different in etravirine treated than among in comparator arms. In large clinical trials as well as open access studies, there were no reported instances of clinically apparent liver injury attributed to etravirine.
Skin rashes occur in 10% to 20% of patients on etravirine usually during the first 2 to 6 weeks of therapy, and this rate is higher than with other antiretroviral regimens or comparator arms and is the major reason for discontinuation of etravirine because of adverse events. The skin rash during etravirine therapy can be accompanied by other signs of hypersensitivity including Stevens Johnson Syndrome and immunoallergic hepatitis. Clinically apparent hepatotoxicity is rare, but cases of hepatitis accompanying rash and signs of hypersensitivity have been reported to the sponsor, some of which have resulted in fatalities. The clinical features of these cases have not been described in detail. Most cases of hypersensitivity hepatitis due to nonnucleoside reverse transcriptase inhibitors arise during the first 6 weeks of therapy and are accompanied by immunoallergic manifestations such as rash, fever, lymphadenopathy and eosinophilia. Recovery is usually prompt after discontinuation, but progressive fatal instances of liver injury can occur.
Likelihood score: D (possible cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Etravirine is excreted in breastmilk in concentrations exceeding the maternal plasma and appears to increase in concentration over time. Until more information becomes available, an alternate agent may be preferred. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
Plasma protein binding is about 99.9% in vitro. In vitro, 99.6% is bound to albumin, and 97.66% - 99.02% is bound to 1-alpha glycoprotein.
References

[1]. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48(12): p. 468.

[2]. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007. 370(9581): p. 39-48.

Additional Infomation
Pharmacodynamics
Clinical trials have shown no prolongation of QT intervals on electrocardiograms after 8 days of dosing.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C20H15BRN6O
Molecular Weight
435.28
Exact Mass
434.049
CAS #
269055-15-4
Related CAS #
Etravirine-d4;1142095-93-9;Etravirine-d8;1142096-06-7
PubChem CID
193962
Appearance
White to off-white solid powder
Density
1.6±0.1 g/cm3
Boiling Point
637.4±65.0 °C at 760 mmHg
Melting Point
265ºC (dec.)
Flash Point
339.3±34.3 °C
Vapour Pressure
0.0±1.9 mmHg at 25°C
Index of Refraction
1.703
LogP
4.19
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
4
Heavy Atom Count
28
Complexity
609
Defined Atom Stereocenter Count
0
InChi Key
PYGWGZALEOIKDF-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
Chemical Name
4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile
Synonyms
R-165335;TMC-125;R165335;TMC125;R 165335; TMC 125;R165335; Etravirine. Intelence.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO:42 mg/mL (96.5 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2974 mL 11.4869 mL 22.9737 mL
5 mM 0.4595 mL 2.2974 mL 4.5947 mL
10 mM 0.2297 mL 1.1487 mL 2.2974 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
CTID: NCT00980538
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-10
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
CTID: NCT04630002
Phase: Phase 1    Status: Completed
Date: 2024-08-29
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
CTID: NCT04273165
Phase: Phase 2    Status: Completed
Date: 2023-03-20
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
CTID: NCT00042289
Phase:    Status: Completed
Date: 2022-07-22
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
CTID: NCT00537394
Phase: Phase 3    Status: Completed
Date: 2021-11-04
View More

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
CTID: NCT01504841
Phase: Phase 1/Phase 2    Status: Completed
Date: 2021-11-02


A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
CTID: NCT04208373
Phase: Phase 1    Status: Completed
Date: 2020-03-26
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
CTID: NCT01641367
Phase: Phase 4    Status: Completed
Date: 2019-03-15
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
CTID: NCT00823979
Phase: Phase 2    Status: Terminated
Date: 2018-12-04
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
CTID: NCT00855335
Phase: Phase 3    Status: Completed
Date: 2018-07-06
Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients
CTID: NCT02818348
Phase: Phase 1    Status: Completed
Date: 2018-03-12
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
CTID: NCT01199731
Phase: Phase 2    Status: Terminated
Date: 2017-11-17
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
CTID: NCT00855413
Phase: Phase 4    Status: Terminated
Date: 2017-10-17
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
CTID: NCT02063360
Phase: Phase 1    Status: Completed
Date: 2017-08-08
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
CTID: NCT00959894
Phase: Phase 2    Status: Completed
Date: 2016-06-06
IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
CTID: NCT00977756
Phase:    Status: Completed
Date: 2015-08-07
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs
CTID: NCT00354627
Phase: Phase 3    Status: Completed
Date: 2015-06-12
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
CTID: NCT00665847
Phase: Phase 2    Status: Completed
Date: 2015-04-23
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
CTID: NCT01422330
Phase: Phase 4    Status: Completed
Date: 2014-10-13
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
CTID: NCT00254046
Phase: Phase 3    Status: Completed
Date: 2014-06-20
A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
CTID: NCT01254656
Phase: Phase 2    Status: Terminated
Date: 2014-06-09
An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
CTID: NCT01615601
Phase:    Status: Completed
Date: 2014-05-22
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
CTID: NCT00359021
Phase: Phase 3    Status: Completed
Date: 2014-05-16
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
CTID: NCT01199939
Phase: Phase 2    Status: Completed
Date: 2013-12-04
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study
CTID: NCT00128830
Phase: Phase 2    Status: Completed
Date: 2013-06-20
Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine
CTID: NCT01876966
Phase: Phase 1    Status: Completed
Date: 2013-06-13
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
CTID: NCT00903682
Phase: Phase 2    Status: Completed
Date: 2013-01-14
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
CTID: NCT01090648
Phase: Phase 1    Status: Completed
Date: 2012-12-11
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
CTID: NCT00867152
Phase: Phase 1    Status: Completed
Date: 2012-02-22
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
CTID: NCT00782301
Phase: Phase 4    Status: Withdrawn
Date: 2012-01-19
Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz
CTID: NCT00792584
Phase: N/A    Status: Completed
Date: 2011-09-12
TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
CTID: NCT00255099
Phase: Phase 3    Status: Completed
Date: 2011-06-15
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
CTID: NCT00740389
Phase: Phase 1    Status: Completed
Date: 2011-06-09
TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
CTID: NCT00828815
Phase: Phase 1    Status: Completed
Date: 2011-06-09
TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
CTID: NCT00111280
Phase: Phase 2    Status: Completed
Date: 2011-05-19
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
CTID: NCT00225303
Phase: Phase 2    Status: Completed
Date: 2011-05-19
--------------------------
Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-02-10
A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with an HIV-RNA plasma viremia below 50 copies/mL
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-05-31
An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-04-23
Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-06-20
An open-label study to evaluate the safety, tolerability and pharmacokinetics of etravirine (ETR) in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infected subjects.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-01-26
Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01).
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-10-20
EVALUACIÓN DE LOS NIVELES DE ETRAVIRINA EN PLASMA SEMINAL EN SUJETOS INFECTADOS POR EL VIH
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-07-14
EVALUACIÓN DE LOS NIVELES DE ETRAVIRINA EN LÍQUIDO CEFALORAQUÍDEO (LCR) EN SUJETOS INFECTADOS POR EL VIH
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-03-28
Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2011-03-22
A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2010-10-12
Concentraciones plasmáticas e intracelulares de Raltegravir y Etravirina administrados una vez al día (800 mg y 400 mg, respectivamente) comparado con su dosificación estándard (400 mg y 200 mg/12 h) en pacientes con infección por el VIH.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-02-18
A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-01-21
PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SWITCHING PROTEASE INHIBITOR TO ETRAVIRINE IN HIV-1-INFECTED SUBJECTS WITH VIREMIA SUPPRESSION (ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LA SIMPLIFICACIÓN DE UN INHIBIDOR DE LA PROTEASA A ETRAVIRINA EN PACIENTES CON INFECCIÓN POR EL VIH-1 EN SUPRESIÓN VIRAL)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-12-03
Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.
CTID: null
Phase:    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2009-11-09
A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combination with ritonavir-boosted atazanavir (ATV/rtv) and 1 NRTI in treatment-experienced HIV-1 infected subjects
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-06-22
A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT OF ANTIRETROVIRAL EXPERIENCED HIV-1 INFECTED SUBJECTS WITH EVIDENCE OF NNRTI RESISTANT HIV-1
CTID: null
Phase: Phase 2    Status: Completed, Prematurely Ended
Date: 2009-05-20
A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral therapy-naïve HIV-1 infected subjects.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-03-31
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
CTID: null
Phase: Phase 4    Status: Trial now transitioned, Ongoing, GB - no longer in EU/EEA
Date: 2009-02-13
A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-01-23
A phase III, double blind, multi centre, randomised placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity to TMC125
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-05-22
Essai pilote évaluant un traitement antirétroviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l’etravirine (TMC125) chez les patients infectés par le VIH-1, en échec virologique et porteurs de virus multi-résistants.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-03-21
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-12-22
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-07-06
A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidence of NNRTI resistance from previous NNRTI use.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-07-05
An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216).
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-06-13
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-12-13
A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-09-28
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-07-15
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks.
CTID: null
Phase: Phase 2, Phase 3    Status: Completed
Date: 2005-06-24
A Phase I, open-label trial to investigate pharmacokinetics, safety
CTID: null
Phase: Phase 1    Status: Completed
Date:

Contact Us